The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1742-2094
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system ; volume:18 ; number:1 ; day:18 ; month:9 ; year:2021 ; pages:1-13 ; date:12.2021
Journal of neuroinflammation ; 18, Heft 1 (18.9.2021), 1-13, 12.2021
- Classification
-
Medizin, Gesundheit
- Creator
-
Correia, Susana S.
Liu, Guang
Jacobson, Sarah
Bernier, Sylvie G.
Tobin, Jenny V.
Schwartzkopf, Chad D.
Atwater, Emily
Lonie, Elisabeth
Rivers, Sam
Carvalho, Andrew
Germano, Peter
Tang, Kim
Iyengar, Rajesh R.
Currie, Mark G.
Hadcock, John R.
Winrow, Christopher J.
Jones, Juli E.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12974-021-02275-z
- URN
-
urn:nbn:de:101:1-2021112807263830655789
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Correia, Susana S.
- Liu, Guang
- Jacobson, Sarah
- Bernier, Sylvie G.
- Tobin, Jenny V.
- Schwartzkopf, Chad D.
- Atwater, Emily
- Lonie, Elisabeth
- Rivers, Sam
- Carvalho, Andrew
- Germano, Peter
- Tang, Kim
- Iyengar, Rajesh R.
- Currie, Mark G.
- Hadcock, John R.
- Winrow, Christopher J.
- Jones, Juli E.
- SpringerLink (Online service)
Other Objects (12)
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators
Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies
The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats
Soluble guanylate cyclase stimulator attenuates acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs
Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat
Protein kinases G as downstream mediators of the antifibrotic effects of stimulators of soluble guanylate cyclase
Soluble guanylate cyclase stimulator reduced the gastrointestinal fibrosis in bleomycin-induced mouse model of systemic sclerosis
Structural studies of soluble guanylate cyclase
Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
Determination of cGMP levels in rodent tissues following oral dosing of a soluble guanylate cyclase stimulator
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators
Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies
The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats
Soluble guanylate cyclase stimulator attenuates acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs
Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat
Protein kinases G as downstream mediators of the antifibrotic effects of stimulators of soluble guanylate cyclase
Soluble guanylate cyclase stimulator reduced the gastrointestinal fibrosis in bleomycin-induced mouse model of systemic sclerosis
Structural studies of soluble guanylate cyclase
Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
Determination of cGMP levels in rodent tissues following oral dosing of a soluble guanylate cyclase stimulator
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with hepatic impairment
Pharmacokinetics of the soluble guanylate cyclase stimulator riociguat in individuals with renal impairment
From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators
Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies
The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats
Soluble guanylate cyclase stimulator attenuates acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs
Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat
Protein kinases G as downstream mediators of the antifibrotic effects of stimulators of soluble guanylate cyclase
Soluble guanylate cyclase stimulator reduced the gastrointestinal fibrosis in bleomycin-induced mouse model of systemic sclerosis
Structural studies of soluble guanylate cyclase
Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)